相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Sodium Benzoate, a D-Amino Acid Oxidase Inhibitor, Added to Clozapine for the Treatment of Schizophrenia: A Randomized, Double-Blind, Placebo-Controlled Trial
Chieh-Hsin Lin et al.
BIOLOGICAL PSYCHIATRY (2018)
Effects of Omega-3 in the treatment of violent schizophrenia patients
Yi Qiao et al.
SCHIZOPHRENIA RESEARCH (2018)
Adjunctive minocycline for schizophrenia: A meta-analysis of randomized controlled trials
Ying-Qiang Xiang et al.
EUROPEAN NEUROPSYCHOPHARMACOLOGY (2017)
Raloxifene Plus Antipsychotics Versus Placebo Plus Antipsychotics in Severely Ill Decompensated Postmenopausal Women With Schizophrenia or Schizoaffective Disorder: A Randomized Controlled Trial
Mark Weiser et al.
JOURNAL OF CLINICAL PSYCHIATRY (2017)
Antioxidant and anti-inflammatory nutrient status, supplementation, and mechanisms in patients with schizophrenia
Sumedha Mitral et al.
PROGRESS IN NEURO-PSYCHOPHARMACOLOGY & BIOLOGICAL PSYCHIATRY (2017)
Raloxifene as an Adjunctive Treatment for Postmenopausal Women With Schizophrenia: A 24-Week Double-Blind, Randomized, Parallel, Placebo-Controlled Trial
Judith Usall et al.
SCHIZOPHRENIA BULLETIN (2016)
A randomized controlled study of the efficacy of six-month supplementation with concentrated fish oil rich in omega-3 polyunsaturated fatty acids in first episode schizophrenia
Tomasz Pawelczyk et al.
JOURNAL OF PSYCHIATRIC RESEARCH (2016)
Vitamin E and essential polyunsaturated fatty acids supplementation in schizophrenia patients treated with haloperidol
Marija Boskovic et al.
NUTRITIONAL NEUROSCIENCE (2016)
Effect of Adjunctive Raloxifene Therapy on Severity of Refractory Schizophrenia in Women A Randomized Clinical Trial
Jayashri Kulkarni et al.
JAMA PSYCHIATRY (2016)
Adjunctive selective estrogen receptor modulator increases neural activity in the hippocampus and inferior frontal gyrus during emotional face recognition in schizophrenia
E. Ji et al.
TRANSLATIONAL PSYCHIATRY (2016)
Marine omega-3 fatty acids and inflammatory processes: Effects, mechanisms and clinical relevance
Philip C. Calder
BIOCHIMICA ET BIOPHYSICA ACTA-MOLECULAR AND CELL BIOLOGY OF LIPIDS (2015)
Adjunctive raloxifene treatment improves attention and memory in men and women with schizophrenia
T. W. Weickert et al.
MOLECULAR PSYCHIATRY (2015)
Inflammation in schizophrenia: A question of balance
Juan C. Leza et al.
NEUROSCIENCE AND BIOBEHAVIORAL REVIEWS (2015)
Neuroinflammation: Ways in Which the Immune System Affects the Brain
Richard M. Ransohoff et al.
NEUROTHERAPEUTICS (2015)
May Non-antipsychotic Drugs Improve Cognition of Schizophrenia Patients?
M. Buoli et al.
PHARMACOPSYCHIATRY (2015)
Neuroinflammation and white matter pathology in schizophrenia: systematic review
Souhel Najjar et al.
SCHIZOPHRENIA RESEARCH (2015)
Sex hormones and oxytocin augmentation strategies in schizophrenia: A quantitative review
Sophie M. Heringa et al.
SCHIZOPHRENIA RESEARCH (2015)
Estradiol for treatment-resistant schizophrenia: a large-scale randomized-controlled trial in women of child-bearing age
J. Kulkarni et al.
MOLECULAR PSYCHIATRY (2015)
Inflammation and immunity in schizophrenia: implications for pathophysiology and treatment
Golam M. Khandaker et al.
LANCET PSYCHIATRY (2015)
Peripheral Inflammation Acutely Impairs Human Spatial Memory via Actions on Medial Temporal Lobe Glucose Metabolism
Neil A. Harrison et al.
BIOLOGICAL PSYCHIATRY (2014)
Biological insights from 108 schizophrenia-associated genetic loci
Stephan Ripke et al.
NATURE (2014)
Pregnenolone treatment reduces severity of negative symptoms in recent-onset schizophrenia: An 8-week, double-blind, randomized add-on two-center trial
Michael S. Ritsner et al.
PSYCHIATRY AND CLINICAL NEUROSCIENCES (2014)
Minocycline add-on to risperidone for treatment of negative symptoms in patients with stable schizophrenia: Randomized double-blind placebo-controlled study
Mohammad-Reza Khodaie-Ardakani et al.
PSYCHIATRY RESEARCH (2014)
Proof-of-concept randomized controlled trial of pregnenolone in schizophrenia
Christine E. Marx et al.
PSYCHOPHARMACOLOGY (2014)
Efficacy of Anti-inflammatory Agents to Improve Symptoms in Patients With Schizophrenia: An Update
Iris E. Sommer et al.
SCHIZOPHRENIA BULLETIN (2014)
Cytokine function in medication-naive first episode psychosis: A systematic review and meta-analysis
Rachel Upthegrove et al.
SCHIZOPHRENIA RESEARCH (2014)
Minocycline supplementation for treatment of negative symptoms in early-phase schizophrenia: A double blind, randomized, controlled trial
Fang Liu et al.
SCHIZOPHRENIA RESEARCH (2014)
Raloxifene adjunctive therapy for postmenopausal women suffering from chronic schizophrenia: a randomized double-blind and placebo controlled trial
Gilda Kianimehr et al.
DARU-JOURNAL OF PHARMACEUTICAL SCIENCES (2014)
Minocycline as Add-On Treatment Decreases the Negative Symptoms of Schizophrenia; A Randomized Placebo-Controlled Clinical Trial
Ahmad Ghanizadeh et al.
RECENT PATENTS ON INFLAMMATION & ALLERGY DRUG DISCOVERY (2014)
N-Acetylcysteine as an Adjunct to Risperidone for Treatment of Negative Symptoms in Patients With Chronic Schizophrenia: A Randomized, Double-Blind, Placebo-Controlled Study
Mehdi Farokhnia et al.
CLINICAL NEUROPHARMACOLOGY (2013)
Can Antipsychotics Improve Social Cognition in Patients with Schizophrenia?
Katarzyna Kucharska-Pietura et al.
CNS DRUGS (2013)
A review of anti-inflammatory agents for symptoms of schizophrenia
William R. Keller et al.
JOURNAL OF PSYCHOPHARMACOLOGY (2013)
Prenatal inflammation and neurodevelopment in schizophrenia: A review of human studies
Brian J. Miller et al.
PROGRESS IN NEURO-PSYCHOPHARMACOLOGY & BIOLOGICAL PSYCHIATRY (2013)
Anti-inflammatory treatment in schizophrenia
Norbert Mueller et al.
PROGRESS IN NEURO-PSYCHOPHARMACOLOGY & BIOLOGICAL PSYCHIATRY (2013)
Prenatal maternal infection, neurodevelopment and adult schizophrenia: a systematic review of population-based studies
G. M. Khandaker et al.
PSYCHOLOGICAL MEDICINE (2013)
Adjunctive Use of Nonsteroidal Anti-inflammatory Drugs for Schizophrenia: A Meta-analytic Investigation of Randomized Controlled Trials
Masahiro Nitta et al.
SCHIZOPHRENIA BULLETIN (2013)
Add-on Treatment of Benzoate for Schizophrenia A Randomized, Double-blind, Placebo-Controlled Trial of D-Amino Acid Oxidase Inhibitor
Hsien-Yuan Lane et al.
JAMA PSYCHIATRY (2013)
A randomized placebo-controlled trial of an omega-3 fatty acid and vitamins E plus C in schizophrenia
H. Bentsen et al.
TRANSLATIONAL PSYCHIATRY (2013)
Delirium is a strong risk factor for dementia in the oldest-old: a population-based cohort study
Daniel H. J. Davis et al.
BRAIN (2012)
Nonsteroidal Anti-Inflammatory Drugs in Schizophrenia: Ready for Practice or a Good Start? A Meta-Analysis
Iris E. Sommer et al.
JOURNAL OF CLINICAL PSYCHIATRY (2012)
Minocycline benefits negative symptoms in early schizophrenia: a randomised double-blind placebo-controlled clinical trial in patients on standard treatment
Imran B. Chaudhry et al.
JOURNAL OF PSYCHOPHARMACOLOGY (2012)
Pharmacological treatment of schizophrenia: a critical review of the pharmacology and clinical effects of current and future therapeutic agents
S. Miyamoto et al.
MOLECULAR PSYCHIATRY (2012)
Effect of the neuroprotective peptide davunetide (AL-108) on cognition and functional capacity in schizophrenia
Daniel C. Javitt et al.
SCHIZOPHRENIA RESEARCH (2012)
Meta-Analysis of Cytokine Alterations in Schizophrenia: Clinical Status and Antipsychotic Effects
Brian J. Miller et al.
BIOLOGICAL PSYCHIATRY (2011)
Immune modulation of learning, memory, neural plasticity and neurogenesis
Raz Yirmiya et al.
BRAIN BEHAVIOR AND IMMUNITY (2011)
Raloxifene as an Adjunctive Treatment for Postmenopausal Women With Schizophrenia: A Double-Blind, Randomized, Placebo-Controlled Trial
Judith Usall et al.
JOURNAL OF CLINICAL PSYCHIATRY (2011)
Inflammatory processes in schizophrenia: A promising neuroimmunological target for the treatment of negative/cognitive symptoms and beyond
Urs Meyer et al.
PHARMACOLOGY & THERAPEUTICS (2011)
Estrogens and men with schizophrenia: Is there a case for adjunctive therapy?
Jayashri Kulkarni et al.
SCHIZOPHRENIA RESEARCH (2011)
Prenatal Infection and Schizophrenia: A Review of Epidemiologic and Translational Studies
Alan S. Brown et al.
AMERICAN JOURNAL OF PSYCHIATRY (2010)
A Double-Blind, Randomized Study of Minocycline for the Treatment of Negative and Cognitive Symptoms in Early-Phase Schizophrenia
Yechiel Levkovitz et al.
JOURNAL OF CLINICAL PSYCHIATRY (2010)
Pregnenolone and Dehydroepiandrosterone as an Adjunctive Treatment in Schizophrenia and Schizoaffective Disorder: An 8-Week, Double-Blind, Randomized, Controlled, 2-Center, Parallel-Group Trial
Michael S. Ritsner et al.
JOURNAL OF CLINICAL PSYCHIATRY (2010)
Adjuvant Aspirin Therapy Reduces Symptoms of Schizophrenia Spectrum Disorders: Results From a Randomized, Double-Blind, Placebo-Controlled Trial
Wijnand Laan et al.
JOURNAL OF CLINICAL PSYCHIATRY (2010)
Neuroprotective effects of ethyl-eicosapentaenoic acid in first episode psychosis: A longitudinal T2 relaxometry pilot study
Stephen J. Wood et al.
PSYCHIATRY RESEARCH-NEUROIMAGING (2010)
Piloting the effective therapeutic dose of adjunctive selective estrogen receptor modulator treatment in postmenopausal women with schizophrenia
Jayashri Kulkarni et al.
PSYCHONEUROENDOCRINOLOGY (2010)
Celecoxib treatment in an early stage of schizophrenia: Results of a randomized, double-blind, placebo-controlled trial of celecoxib augmentation of amisulpride treatment
Norbert Mueller et al.
SCHIZOPHRENIA RESEARCH (2010)
CONSORT 2010 Statement: updated guidelines for reporting parallel group randomised trials
Kenneth F. Schulz et al.
BMJ-BRITISH MEDICAL JOURNAL (2010)
Neural basis of psychosis-related behaviour in the infection model of schizophrenia
Urs Meyer et al.
BEHAVIOURAL BRAIN RESEARCH (2009)
Neuroinflammation in Schizophrenia-Related Psychosis: A PET Study
Janine Doorduin et al.
JOURNAL OF NUCLEAR MEDICINE (2009)
Proof-of-Concept Trial with the Neurosteroid Pregnenolone Targeting Cognitive and Negative Symptoms in Schizophrenia
Christine E. Marx et al.
NEUROPSYCHOPHARMACOLOGY (2009)
Cytokines and schizophrenia: Microglia hypothesis of schizophrenia
Akira Monji et al.
PSYCHIATRY AND CLINICAL NEUROSCIENCES (2009)
The MATRICS consensus cognitive battery, part 1: Test selection, reliability, and validity
Keith H. Nuechterlein et al.
AMERICAN JOURNAL OF PSYCHIATRY (2008)
Estrogen in severe mental illness - A potential new treatment approach
Jayashri Kulkarni et al.
ARCHIVES OF GENERAL PSYCHIATRY (2008)
Microglia Activation in Recent-Onset Schizophrenia: A Quantitative (R)-[11C]PK11195 Positron Emission Tomography Study
Bart N. van Berckel et al.
BIOLOGICAL PSYCHIATRY (2008)
N-acetyl cysteine as a glutathione precursor for schizophrenia - A double-blind, randomized, placebo-controlled trial
Michael Berk et al.
BIOLOGICAL PSYCHIATRY (2008)
Norms and standardization of the Brief Assessment of Cognition in Schizophrenia (BACS)
Richard S. E. Keefe et al.
SCHIZOPHRENIA RESEARCH (2008)
Improvement of cognitive functions in chronic schizophrenic patients by recombinant human erythropoietin
H. Ehrenreich et al.
MOLECULAR PSYCHIATRY (2007)
Celecoxib as adjunctive therapy in schizophrenia: A double-blind, randomized and placebo-controlled trial
Shahin Akhondzadeh et al.
SCHIZOPHRENIA RESEARCH (2007)
Effect of hormone replacement therapy on cognitive function in women with chronic schizophrenia
Young-Hoon Ko et al.
INTERNATIONAL JOURNAL OF PSYCHIATRY IN CLINICAL PRACTICE (2006)
The effects of eicosapentaenoic acid in tardive dyskinesia: A randomized, placebo-controlled trial
Robin Emsley et al.
SCHIZOPHRENIA RESEARCH (2006)
Treatment of schizophrenia negative symptoms: Future prospects
SM Erhart et al.
SCHIZOPHRENIA BULLETIN (2006)
Abnormal Involuntary Movement Scale (AIMS) and Extrapyramidal Symptom Rating Scale (ESRS): Cross-scale comparison in assessing tardive dyskinesia
GM Gharabawi et al.
SCHIZOPHRENIA RESEARCH (2005)
Size of burden of schizophrenia and psychotic disorders
W Rössler et al.
EUROPEAN NEUROPSYCHOPHARMACOLOGY (2005)
Celecoxib augmentation of continuously Ill patients with schizophrenia
MH Rapaport et al.
BIOLOGICAL PSYCHIATRY (2005)
Clinical effects of COX-2 inhibitors on cognition in schizophrenia
N Müller et al.
EUROPEAN ARCHIVES OF PSYCHIATRY AND CLINICAL NEUROSCIENCE (2005)
Theories of schizophrenia: a genetic-inflammatory-vascular synthesis
DR Hanson et al.
BMC MEDICAL GENETICS (2005)
COX-2 inhibition as a treatment approach in schizophrenia:: Immunological considerations and clinical effects of celecoxib add-on therapy
N Müller et al.
EUROPEAN ARCHIVES OF PSYCHIATRY AND CLINICAL NEUROSCIENCE (2004)
Longitudinal studies of cognition and functional outcome in schizophrenia: implications for MATRICS
MF Green et al.
SCHIZOPHRENIA RESEARCH (2004)
Adjunctive estrogen treatment in women with chronic schizophrenia: a double-blind, randomized, and placebo-controlled trial
S Akhondzadeh et al.
PROGRESS IN NEURO-PSYCHOPHARMACOLOGY & BIOLOGICAL PSYCHIATRY (2003)
Omega-3 fatty acids in inflammation and autoimmune diseases
AP Simopoulos
JOURNAL OF THE AMERICAN COLLEGE OF NUTRITION (2002)
Randomized, placebo-controlled study of ethyl-eicosapentaenoic acid as supplemental treatment in schizophrenia
R Emsley et al.
AMERICAN JOURNAL OF PSYCHIATRY (2002)
Beneficial antipsychotic effects of celecoxib add-on therapy compared to risperidone alone in schizophrenia
N Müller et al.
AMERICAN JOURNAL OF PSYCHIATRY (2002)
A dose-ranging exploratory study of the effects of ethyl-eicosapentaenoate in patients with persistent schizophrenic symptoms
M Peet et al.
JOURNAL OF PSYCHIATRIC RESEARCH (2002)
A placebo-controlled trial of omega-3 fatty acid (ethyl eicosapentaenoic acid) supplementation for residual symptoms and cognitive impairment in schizophrenia
WS Fenton et al.
AMERICAN JOURNAL OF PSYCHIATRY (2001)
Two double-blind placebo-controlled pilot studies of eicosapentaenoic acid in the treatment of schizophrenia
M Peet et al.
SCHIZOPHRENIA RESEARCH (2001)
Estrogen - a potential treatment for schizophrenia
J Kulkarni et al.
SCHIZOPHRENIA RESEARCH (2001)
分享论文
